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ABSTRACT 
A variety of microparticles have been proposed for the sustained and localized delivery of drugs 
whit the objective of increasing therapeutic indexes by circumventing filtering organs and 
biological barriers. Yet, the geometrical, mechanical and therapeutic properties of such 
microparticles cannot be simultaneously and independently tailored during the fabrication process 
in order to optimize their performance. In this work, a top-down approach is employed to realize 
micron-sized polymeric particles, called microPlates (PLs), for the sustained release of 
therapeutic agents. PLs are square hydrogel particles, with an edge length of 20 m and a height 
of 5 m, made out of poly(lactic-co-glycolic acid) (PLGA). During the synthesis process, the PL 
Young’s modulus can be varied from 0.6 to 5 MPa by changing PLGA amounts from 1 to 7.5 mg, 
without affecting the PL geometry. Within the porous PL matrix, different classes of therapeutic 
payloads can be incorporated including molecular agents, such as the anti-inflammatory 
dexamethasone (DEX), and nanoparticles, containing themselves imaging and therapeutic 
molecules. As a proof of principle, PLs are loaded with free DEX and 200 nm spherical polymeric 
nanoparticles, carrying DEX molecules (DEX-SPNs). Electron and fluorescent confocal 
microscopy analyses document the uniform distribution and stability of molecular and nano-agents 
within the PL matrice. This multiscale, hierarchical microparticle releases DEX for at least 10 
days. The inclusion of DEX-SPNs serves to minimize the initial burst release and modulate the 
diffusion of DEX molecules out of the PL matrix. The pharmacological and therapeutic 
properties together with the fine tuning of geometry and mechanical stiffness make PLs a unique 
polymeric depot for the potential treatment of cancer, cardiovascular and chronic, inflammatory 
diseases.  
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INTRODUCTION 
The systemic administration of nanoparticles for the detection and treatment of diseased tissues is 
progressively shaping up as a successful strategy, as demonstrated by the growing number of 
clinical trials based on nanomedicines.1 The biophysical mechanisms regulating the accumulation 
of blood-borne nanoparticles within malignant tissues are mostly associated with the tortuosity 
and hyper-permeability of the diseased microcirculation, as compared to normal vascular beds.2-3 
For the same mechanisms, a portion of intravenously injected nanoparticles tends also to 
accumulate within filtering organs, such as the liver and spleen, which are characterized by 
discontinuous and permeable vascular walls.4 A variety of approaches have been proposed to 
reduce the unspecific deposition of nanomedicines within these filtering organs, including the 
proper tailoring of the nanoparticle surface, geometrical and mechanical properties.5-7 An 
alternative approach relies on drug depots, which follow a different strategy. These are realized by 
the intra-tissue deposition of nano- and micro-particles, nanofibers and gels, and allow for the 
sustained and long-term release of large amounts of therapeutic agents. Importantly, these agents 
are directly deployed from the depot within the diseased tissue bypassing filtering organs and 
biological barriers, such as the blood brain, the intestinal and lung epithelial barriers.8 As such, 
drug depots could represent a valuable alternative to the systemic administration of therapeutics in 
a number of applications. This has been already shown clinically and pre-clinically for cancer, 
cardiovascular, and localized, chronic inflammatory diseases.9-11 
 
In the post-surgical treatment of brain cancers, the local delivery of carmustine from biodegradable 
polymeric wafers is commonly practiced in the clinic and has contributed to improve the life 
expectation of patients diagnosed with high grade gliomas.9, 12 In this application, polymeric 
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wafers are deposited on the surface of the tumor’s resected cavity and release their cytotoxic 
content for about 6 days with the objective of removing residual cancer cells. A similar strategy 
has been proposed for the treatment of other deadly malignancies, including pancreatic, liver and 
lung carcinomas.13-15 Drug depots have been also developed for the management of cardiovascular 
diseases, chronic inflammatory diseases, and brain disorders. For instance, drug-coated balloons 
and medicated stents are used for modulating the risk of restenosis in atherosclerosis.16-17 After 
recanalization, thin films of cytotoxic agents are deposited onto the injured vasculature with the 
objective of inhibiting local cell growth and the risk of de novo occlusions. In osteoarthritis, nano 
and microparticles of chitosan and other polymers have been loaded with a variety of agents, 
including anti-inflammatory molecules, analgesics, growth factors, and injected intra-articularly 
to induce tissue repair and resolve local inflammation.18-19 Similar approaches have been proposed 
for endodontic applications where nano and microparticles were used for the local delivery of anti-
microbial and anti-inflammatory agents, and growth factors.20-21 Finally, micron-sized polymeric 
particles have been proposed for delivering drugs directly within specific areas of the brain for the 
treatment of diverse disorders, including epilepsy22, Parkinson’s disease23, and behavioral 
disorders.24 
 
As described above, most local drug depots are realized with nano/micro-particles, nanofibers, 
polymeric films, and gels directly inoculated at the diseased site.8 The efficacy of the system is 
dictated by the loading and release profiles of the active agents as well as by the spatial distribution 
and integration of the depot with the surrounding tissue.8, 25 Following this notion, in this work, 
innovative modular and hierarchical polymeric microparticles – the microplates (PLs) – are 
realized using a top-down fabrication approach where the size, shape, surface properties and 
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mechanical stiffness can be simultaneously and independently tailored during the synthesis 
process.26-27 In the present configuration, PLs present a square base of 20 m, a height of 5 m, 
are made out of PLGA and their stiffness is finely tuned between about 0.5 and 5 MPa. 
Furthermore, PLs are loaded with different molecular agents and nanoparticles returning a 
multifunctional, hierarchical system for local drug delivery. As a proof of principle, PLs are 
loaded with the anti-inflammatory molecule dexamethasone acetate (DEX) and with 200 nm 
spherical nanoparticles, loaded themselves with DEX. The anti-inflammatory efficacy of PLs is 
tested on two phagocytic cell types, namely RAW 264.7 cells and bone marrow derived monocytes 
(BMDMs). 
 
MATERIALS AND METHODS 
MATERIALS 
Polydimethylsiloxane (PDMS) (Sylgard 184) was purchased from Dow Corning (Midland, 
Michigan, USA). Poly(vinyl alcohol) (PVA), poly(lactic-co-glycolic) acid (PLGA) (50:50), 
dexamethasone acetate (DEX), rhodamine B (RhB), MTT assay, sodium phosphate dibasic 
dehydrate, sodium phosphate monobasic monohydrate, acetonitrile, macrophage colony- 
stimulating factor (M-CSF), bacterial lipopolysaccharides (LPS) paraformaldehyde (PFA) and 
trifluoroacetic acid (TFA) were purchased from Sigma Aldrich (Saint Louis, Missouri, USA). All 
the lipids were purchased from Avanti Polar Lipid: 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (sodium salt) (DSPE-PEG-COOH) 
and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC). Curcumin (CURC) was purchased 
from Alfa Aesar (Haverhill, Massachusetts, USA). 20 nm gold nanoparticles were purchased from 
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Nanopartz Inc. (USA) Polycarbonate membrane filters were purchased from Sterlitech 
Corporation (USA). Wheat germ agglutinin (WGA), 4',6-diamidino-2-phenylindole (DAPI), 
RNAeasy Plus Mini Kit (50) purchased from Qiagen. PBS, RT-PCR reagents and gene specific 
primers were purchased from Thermo Scientific (USA). RAW 264.7 cell line was obtained from 
American Type Culture Collection (ATCC, LGC Standards, Teddington, UK). High-glucose 
Dulbecco's modified Eagle's Minimal Essential Medium (DMEM) and heat-inactivated fetal 
bovine serum (FBS) were obtained from GIBCO (Invitrogen Corporation, Giuliano Milanese, 
Milan, Italy). Lowicryl® K11M resin was purchased from Chemische Werke Lowi (Germany). 
 
METHODS 
Fabrication Process of the MicroPlates. The synthesis of the microplates (μPLs) follows a multi-
steps process, partially described in previous works by the authors and other scientists.28-29 First, a 
silicon master template is fabricated using Direct Laser Writing (DLW). The master template is a 
silicon substrate on which arrays of square wells are realized with an edge length of 20 µm and a 
depth of 5 µm, and each arrays is separated by a 3 µm gap. Then, a PDMS replica of the silicon 
master template is obtained by covering it with a mixture of PDMS and elastomer (10:1, v/v). The 
resulting sample is left in a vacuum chamber to remove bubbles formed during the mixing process 
and polymerized at 60 °C for 4h. Then, the PDMS template is peeled off the silicon substrate and 
used to obtain a PVA template, by pouring a PVA solution (3.5% w/v, in deionized water) on its 
patterned surface. The resulting PVA film is dried at 60 °C and finally peeled off the PDMS 
template. Thus, the PVA film has the same arrays of wells as the original silicon master template. 
In the last step, μPLs are obtained by spreading the mixture of PLGA and the desired payload onto 
the PVA wells. After solvent evaporation, the loaded PVA templates are dissolved in DI water at 
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room temperature in ultrasonic bath. Released μPLs are purified from PVA solution by using 
polycarbonate membrane filters (30 μm) and collected through sequential centrifugations (1,717 g 
for 5 min). Different amounts of PLGA, namely 1, 5 and 7.5 mg, are used in order to modulate 
μPL rigidity. μPLs loaded with dexamethasone acetate (DEX-μPLs) or curcumin (CURC-μPLs) 
are realized by dispersing within the polymeric mixture 500 μg of dexamethasone acetate (DEX) 
or curcumin (CURC), respectively. For the degradation studies, 2 μg of fluorescent Rhodamine B 
(RhB) are dissolved in the polymeric mixture, thus replacing the drug molecules.  
 
Physicochemical characterization of the MicroPlates. The geometry and physicochemical 
properties of μPLs are characterized using different techniques. μPLs size and shape analyses are 
performed via scanning electron microscopy (SEM, Elios Nanolab 650, FEI). Briefly, a drop of 
sample is spotted on a silicon template and uniformly sputtered with gold to increase the contrast 
and reduce sample damaging. An acceleration voltage of 5 - 15 keV is used for SEM imaging. 
μPLs average size and distribution are also obtained using a Multisizer 4 Coulter Particle Counter 
(Beckman Coulter, CA). Briefly, μPLs are resuspended in the electrolyte solution and analyzed, 
following protocols described by the vendor. The μPLs electrostatic surface charge is determined 
using a Zetasizer Nano (Malvern, U.K.).  
 
Biofrmaceutical characterization of the MicroPlates. For measuring DEX loading and 
encapsulation efficiency (LE and EE, respectively) into DEX-μPLs, samples are lyophilized, 
dissolved in acetonitrile/H2O (1:1, v/v) and analyzed by high-performance liquid chromatography 
(HPLC) (Agilent 1260 Infinity, Germany), equipped with a 100 μl sample loop injector. A 
C18column (4.6×250 mm, 5 μm particle size, Agilent, USA) was used for the chromatographic 
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separation. The DEX was eluted under isocratic condition using a binary solvent system 
(H2O+0.1% (v/v) TFA: AcN+0.1% (v/v) TFA, 50:50 v/v) pumped at a flow rate of 1.0 ml/min. 
The UV detection was set at 240 nm. The retention time of DEX was 3.65 min. An external 
standard curve in a linear concentration ranging from 1 to 300 μg/ml was used for the 
quantification of DEX. A standard solution (10 mg/ml in acetonitrile) was used for the construction 
of the standard curve. The amount of DEX was determined using the following equation (r2= 
0.9997): 
Eq. 1    AUC = 2.5118x - 1.338  
where x is the drug concentration (μg/ml). HPLC analysis showed that no interference was 
determined by the various components of MicroPlates. 
LE and EE are determined using the following equations:  
𝐿𝐸(%) =
 𝐷𝐸𝑋 𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
𝑥100 
𝐸𝐸(%) =
 𝐷𝐸𝑋 𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝐷𝐸𝑋 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑓𝑒𝑒𝑑𝑖𝑛𝑔 𝑎𝑚𝑜𝑢𝑛𝑡 
𝑥100 
 
To study DEX release kinetics, 200 μl of DEX-PLs solution are placed into Slide-A-Lyzer MINI 
dialysis microtubes with a molecular cut-off of 10 kDa (Thermo Scientific) and then dialyzed 
against 4 L of PBS buffer (pH 7.4) or phosphate saline buffer (pH 5.5, 1 X) at 37 °C. For each time 
point, three samples are collected and centrifuged (1,717 g for 5 min). Pellets are then dissolved 
in acetonitrile/H2O (1:1, v/v) and analyzed by HPLC. The experimental data are fitted by using 
the Ritger-Peppas model for controlled not swellable drug delivery systems:30  
𝑌 = 𝐾∗x𝑛 
where, Y represents the drug percentage released, x is the time of observation, and k and n are the 
fitting parameters.  
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Stability of the MicroPlates. The stability of μPLs is evaluated by fluorescence microscopy 
(Leica 6000, Wetzlar, Germania) and SEM analysis. 200 l of empty and RhB-μPLs were 
incubated in PBS buffer (pH 7.4) or phosphate saline buffer (pH 5.5, 1 X) under mechanically 
stirring at 37 °C. At different time points (1, 3, 6 and 10 days), samples are analyzed to monitor 
structural and morphological changes. 
 
Toxicity and therapeutic efficacy of the dexamethasone-loaded MicroPlates. RAW 264.7 cells 
are cultured at 37 °C in 5% CO2, in high-glucose DMEM, supplemented with 10% FBS and 1% 
L-Glutamine, according to ATCC instructions. Cells are seeded into 96-well plates at a density of 
5×103 cells per well and incubated for 24h. Cells are treated with different concentrations of free 
DEX and DEX-μPLs (namely, 0.1, 0.5, 1, 10 and 30 μM of DEX in both cases) or empty μPLs, at 
cell:µPLs ratios of 1:0.01, 1:0.05, 1:0.1, 1:1 and 1:4, to match the number of µPLs used in the case 
of DEX-µPLs. MTT solution is added for 4 h and formazan crystals dissolved in ethanol. 
Absorbance is measured at 570 nm, using 650 nm as reference wavelength (Tecan, Männedorf, 
Swiss). The percentage of cell viability is assessed according to the following equation: 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =
𝐴𝑏𝑠𝑇
𝐴𝑏𝑠𝐶 
𝑥100 
 
where AbsT is the absorbance of treated cells and AbsC the absorbance of control (untreated) cells. 
To investigate the anti-inflammatory activity of DEX-μPLs towards stimulated macrophages, the 
expression levels of three pro-inflammatory cytokines, namely TNF-α, IL-1β, and IL-6, are 
evaluated in RAW 264.7 cells and rat bone marrow-derived macrophages (BMDMs). For BMDMs 
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harvesting, rat femurs are flushed 4 times with 500 µl of PBS after cutting bones extremities. Cells 
suspension is filtered using 70 µm cell strainers and centrifuged at 72 g for 8 min. Cells are plated 
in Petri dishes and after 3 days, the medium is changed in order to remove unattached cells. 
BMDMs are used after 4 more days. BMDMs are cultured in DMEM supplemented with 15% 
FBS, 1% penicillin/streptomycin and rat M-CSF (according to vendor indications). Both cells are 
cultured in controlled environmental conditions (37 °C in 5% CO2) and are seeded into 6-wells 
plates at a density of 3105 cells per well for 24h. 
Cells are treated with DEX-μPLs at different concentrations and incubated for 5 h. Then, bacterial 
lipopolysaccharides (LPS) are added at a concentration of 100 ng/ml and incubated for 4 h. At the 
end, RNA is extracted using RNAeasy Plus Mini Kit (Qiagen) and quantified by NanoDrop2000 
(Thermo Scientific, Waltham, Massachusetts, USA). Real-time RT-PCR is used to measure 
mRNA levels of inflammatory cytokines. For each condition, samples are in triplicate. RT-PCR 
reactions are carried out using a Power SYBR Green RNA-to-CT 1-Step Kit (Applied 
Biosystems). Reactions are performed in a final volume of 20 µl. Oligonucleotide primer pairs are 
as follows: for GAPDH, 5’-GAACATCATCCCTGCATCCA-3’ and 5’-
CCAGTGAGCTTCCCGTTCA-3’; for TNF-α, 5’-GGTGCCTATGTCTCAGCCTCTT-3’ and 5’-
GCCATAGAACTGATGAGAGGGAG-3’; for IL-1β, 5’-TGGACCTTCCAGGATGAGGACA-
3’ and 5’-GTTCATCTCGGAGCCTGTAGTG-3’; for IL-6, 5’-
TACCACTTCACAAGTCGGAGGC-3’ and 5’-CTGCAAGTGCATCATCGTTGTTC-3’. 
 
Mechanical characterization of the MicroPlates. The atomic force microscopy (AFM) is used 
to measure the stiffness of μPLs. Before the deposition of the sample, to promote adhesion and 
prevent μPLs movement during the analysis, few drops of 10-2 M poly(iminoethylene) (PEI) are 
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spotted on a microscope slide, since PEI is positively charged and supports electrostatic 
interactions with the negatively charged PLGA carboxylic terminations. After few minutes, the 
excess of PEI is removed and 10 μl of sample are placed on the slide. AFM analysis is performed 
using the Nanowizard II AFM (JPK Instruments, Berlin, Germany), mounted on an Axio Observer 
D1 inverted optical microscope (Carl Zeiss, Oberkochen, Germany). Quantitative imaging (QI) 
data set are acquired in liquid, to better mimic physiological environment, using DNP V-shaped 
silicon nitride cantilevers, with nominal spring constant ranging from 0.12 to 0.48 N/m, resonance 
frequency in air 40-75 kHz, and a silicon nitride tip with typical curvature radius 20-60 nm (Bruker, 
Billerica, MA, US). The maximum force applied to the sample is 1 nN.  
 
Preparation of Spherical Polymeric Nanoparticles (SPNs). Spherical polymeric nanoparticles 
are prepared by a slightly modified oil-in-water (O/W) emulsion/solvent evaporation technique, as 
compared to previous work of the authors and other scientists.31-32 Briefly, 300 µl of DEX solution 
(6.66 mg/ml, in acetone) is added at 450 µl of organic solution containing PLGA (1 mg, in 
chloroform), DPPC (100 g in chloroform) and mixed using a probe sonicator for 15 sec at 60% 
Amplitude. This mixture is added drop by drop into 3 ml of 4% ethanol containing 110 g of 
DSPE-PEG-COOH and sonicated for 1 min at 60% Amplitude. The resulting emulsion is placed 
under reduced pressure and magnetic stirring to foster the evaporation of the organic solvents. 
After the complete removal of organic solvents, the obtained nanoparticles are purified through 
centrifugation. To remove the debris of the synthesis procedure, at first the solution is centrifuged 
at 452 g for 2 min, and then SPNs undergo several centrifugations at 18,213 g  for 15 min to 
remove the unloaded drug. In order to demonstrate SPNs integrity after loading into μPLs, DEX 
is replaced with gold nanoparticles, and part of DSPE-PEG is substituted with DSPE-Cy5. 
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Characterization of DEX-loaded Spherical Polymeric Nanoconstructs. Average size, size 
distribution and zeta potential of DEX-SPNs are analyzed using Dynamic Light Scattering (DLS). 
Samples are diluted with isosmotic double distilled water (1:10 v/v) to avoid multiscattering 
phenomena and analyzed at 25 °C with Zetasizer Nano (Malvern, U.K.), , equipped with a 4.5 mW 
laser diode, operating at 670 nm as a light source, and the scattered photons detected at 173°. A 
third order cumulative fitting autocorrelation function was applied to measure average size and 
size distributions. The analysis was carried out according to the following instrumental set up: (a) 
a real refractive index of 1.59;(b) an imaginary refractive index of 0.0; (c) a medium refractive 
index of 1.330; (d) a medium viscosity of 1.0 mPa × s; and (e) a medium dielectric constant of 
80.4. DEX loading (LE) and encapsulation efficiency (EE) into DEX-SPNs are measured as 
previously reported. For the release kinetics, 200 μl of samples were placed into Slide-A-Lyzer 
MINI dialysis microtubes with a molecular cut-off of 10 kDa (Thermo Scientific) and then 
dialyzed against 4 L of PBS buffer (pH 7.4) at 37 °C. For each time point, three samples were 
collected and centrifuged at 18,213 g for 15 min. Pellets were then dissolved in acetonitrile/H2O 
(1:1, v/v) and analyzed by HPLC.  
 
Preparation and characterization of SPNs-loaded MicroPlates. DEX-SPNs-μPLs are 
synthesized using the protocol used for DEX-μPLs fabrication, with some modifications. To 
prevent DEX-SPNs damaging during the synthesis process, they are added to a 20% (w/v) PVA 
aqueous solution, under magnetic stirring, for 15 min, in order to get a PVA coating. Subsequently, 
PVA coated DEX-SPNs are purified using centrifugation and finally added to the polymeric 
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mixture (5 mg of PLGA) and spread onto the PVA template. Then DEX-SPNs-µPLs are released, 
purified, and characterized as above reported for DEX-µPLs.  
To assess their distribution and their integrity after the loading process into µPLs, gold 
nanoparticles-loaded Cy5-tagged-SPNs (Au-Cy5-SPNs) are loaded into CURC-µPLs and then 
analyzed using Nikon A1 confocal microscopy (Dexter, MI) and a JEOL JEM 1011TEM , 
operating with an acceleration voltage of 100 kV and equipped with a 11 Mp fiber optical charge 
coupled device (CCD) camera (GATAN Orius 830). For TEM analysis, µPLs from a suspension 
are dried onto glass slide and embedded into Lowicryl® K11M resin. The resin is polymerized for 
48h under UV lamp (wavelength 365 nm) and then cut using LEICA EM UC6 ultra-microtome 
and ultra sonic 35° DIATOME diamond knife.  
Finally, for determine any possible interaction with other cells, more similar to soft tissues, human 
fibroblasts cells were cultured at 37 °C in 5% CO2, in DMEM, supplemented with 10% FBS and 
1% L-Glutamine. Cells were seeded into 8 chambered cover glass system (Lab Teck II, Thermo 
Scientific, USA) at a density of 20 × 103 cells per well and incubated for 24h. Cells are incubated 
with Au-Cy5-SPNs-loaded CURC-µPLs for 1h. Cells are fixed using 4% PFA and stained with 
WGA  and DAPI, according to vendor indications. Samples were analyzed using confocal 
microscopy Nikon A1 (Dexter, MI). 
 
Statistics analysis. All data are represented as the average ± standard deviation (SD) of 3 different 
measurements, unless differently specified. The statistical significant difference was assessed 
using ANOVA test, with Tukey’s Multiple Comparison Test as post-hoc test. For the fitting of 
release curves, the extra sum-of-square F test is performed. A p value ≤ 0.05 is considered 
statistically significant.  
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RESULTS AND DISCUSSION 
Preparation and physicochemical characterization of MicroPlates. Microplates (μPLs) were 
prepared following different sequential steps, as schematically reported in Figure.1A. The first 
step was the fabrication of a silicon master template with specific geometrical features. This 
original template was replicated into a polydimethylsiloxane (PDMS) template and then into a 
sacrificial polyvinyl alcohol (PVA) template, as described in the Methods section. A polymeric 
mixture was carefully deposited on the PVA template to fill up all square wells. Finally, the PVA 
template loaded with the polymeric mixture was dissolved in water, thus releasing the μPLs. The 
pictures in Figure.1B show, from left to right, a scanning electron microscopy (SEM) image of 
the original silicon master template with arrays of wells; a SEM microscopy image of the PDMS 
template with arrays of pillars; a fluorescent microscopy image of a PVA template carrying 
curcumin-loaded μPLs (green fluorescence); and a fluorescent microscopy image of free 
curcumin-loaded μPLs, released from the PVA template. 
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Figure.1. MicroPlates (µPLs) fabrication process. A. Sequential steps in the fabrication of 20  
20  5 m MicroPlates (µPLs). A silicon master template (grey) is fabricated via direct laser 
writing and replicated into a PDMS template (yellow), whose pattern is then transferred into a 
sacrificial PVA template (white). This PVA template is loaded with the polymeric paste 
constituting the final µPLs and enclosing the imaging and therapeutic payloads. µPLs are released 
and collected upon dissolution in DI water of the sacrificial PVA template; B. From the left to the 
right, SEM images of silicon and PDMS templates, and optical microscopy images of the PVA 
loaded with the polymeric paste and released µPLs. 
 
Curcumin for its intrinsic fluorescence was used for microscopy analysis. Curcumin-loaded µPLs 
(CURC- µPLs) were obtained by depositing a paste of poly(lactic-co-glycolic acid) (PLGA) and 
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curcumin within the sacrificial PVA template. MicroPlates were characterized using different 
techniques (Figure.2). In particular, a scanning electron microscopy (SEM) image is reported in 
Figure.2A, showing the specific geometry of μPLs: a square shape with edge length of about 20 
μm and a height of about 5 μm, which precisely fit the size and shape of the wells in the original 
master silicon template. A size distribution analysis via Multisizer showed a single peak of ~15 
μm with a relatively narrow distribution (Figure.2B). Indeed, given the non-spherical shape of the 
μPLs, the instrument returns an average characteristic size rather than the actual edge length of the 
particle. The µPL eletrostatic surface charge was of -17.9 ± 5.1 mV, which is due to the carboxylic 
termination on the PLGA chains. Figure.2C shows a confocal fluorescent image of CURC-μPLs 
inside the PVA template as maximum intensity projections. Side projections of a single μPL are 
also provided, demonstrating the homogeneous distribution of curcumin within the PLGA matrix 
and confirming the actual square geometry of the μPLs. Figure.2D shows a tri-dimensional 
reconstruction of a single μPL. Altogether the data suggest that this top-down fabrication strategy 
can precisely tailor the size and shape of μPLs, as already shown by the authors at smaller scales.26 
Moreover, as reported in Figure.2E, µPLs are comparable in size with the nuclei of epithelial cells 
(human fibroblasts) and properly interacts with the surrounding biological environment, without 
being internalized by cells(Figure.S1A and B). This would favor the µPL integration with the 
actual tissue in vivo. 
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Figure.2. Geometrical characterization of microplates (µPLs). A. SEM image of µPLs, 
showing the characteristic 20 × 20 × 5 µm square shape; B. Size characterization of µPLs via 
Multisizer analysis; C. Fluorescence confocal microscopy analysis of µPLs loaded with curcumin 
(green) with side views; D. Fluorescence confocal tri-dimensional reconstruction of a single µPL; 
E CURC-µPLs on a human fibroblast monolayer. 
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Biopharmaceutical characterization of Dexamethasone-loaded MicroPlates. DEX was used 
as a ‘model drug’ in that it is one of the most commonly prescribed corticosteroid for the treatment 
of moderate to severe pains, fever and inflammation, which are symptoms quite common to many 
pathological conditions.33 The three different configurations, namely 1, 5 and 7.5 mg PLGA, were 
characterized in terms of yielding, loading (LE) (Figure.3A and B), DEX amounts per μPL, and 
encapsulation efficiency (EE%) (Figure.S2A and B). For the yielding, which is defined as the 
percentage of released μPLs over the number of wells in the original silicon template, a similar 
number of μPL/template was generated in all the three configurations. This was about 6.5 × 105 
particles with a total yielding close to 40% for all considered amounts of PLGA (Figure.3A). On 
the other hand, loading decreases steadily moving from 1.0 to 7.5 mg PLGA µPLs. Specifically, 
LE is equal to 12.70 ± 1.25% for the 1 mg PLGA particles and decreases up to 4.45 ± 0.70% for 
the 7.5 mg PLGA particles (Figure.3B), in a statistically significant manner (p < 0.05). This 
behavior was expected in that LE is calculated as the weight of the drug over the total weight of 
the particle, which indeed grows linearly with the amount of PLGA. Furthermore, both the amount 
of DEX per µPL and the encapsulation efficiency (Figure.S2A and B) showed a modest advantage 
for the 5 mg PLGA formulation as compared to the others. Specifically, the DEX loaded amount 
was 197.38 ± 9.07 pg with an encapsulation efficiency of 11.60 ± 1.45%. This is probably due to 
the slightly smaller yielding for the 1 mg µPLs together with the denser matrix for the 7.5 mg of 
PLGA. 
The DEX release kinetics from µPLs made out of 1.0, 5.0 and 7.5 mg of PLGA were determined 
under physiological (PBS; pH 7.4; 37 C) and pathophysiological (PBS; pH 5.5; 37 C) conditions, 
with the latter simulating the acidic microenvironment, typical of an inflamed tissue.34 Data are 
shown in Figure.3C and D, whit grey, orange and blue lines representing the 1.0, 5.0 and 7.5 mg 
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cases, respectively. For the normal condition, about 60% of DEX was released within the first 8 h, 
whereas the remaining amount of DEX is slowly and continuously released up to 10 days. The 
initial rapid release should be associated with the drug molecules residing close to the particle 
surface, whereas the following slow-release phase could rely on the diffusion of the inner 
molecules towards the outer µPL edges. The drug release profiles for the 1.0, 5.0 and 7.5 mg of 
PLGA µPLs were similar. The release profiles under pathophysiological conditions (pH 5.5) are 
given in Figure.3D, documenting a slow linear phase followed by an initial burst. The faster 
release within the first 4 h, as compared to physiological conditions, might depend on the more 
rapid dissociation of the adsorbed drug, because of its electrostatic nature. These results would 
suggest that overall the release profile is not strongly influenced by the pH, and thus by polymer 
degradation within the considered period, but it is mainly controlled by DEX diffusion out of the 
matrix. In fact, it is well known that PLGA particle degradation is an autocatalytic process which 
starts from the inside of the matrix.35 In our experiments, the presence of an acidic 
microenvironment could mainly promote the surface erosion of the particles and facilitate the 
escape of the outer DEX molecules. 
In order to verify this matrix biodegradation, µPLs loaded with the red fluorescent dye Rhodamine 
B (RhB-µPLs) were synthetized and characterized over time for possible morphological changes. 
Figure.3E reports bright field, fluorescent and scanning electron microscopy images, taken at 
different time points, upon µPLs exposure to physiological and pathophysiological conditions. At 
day 1, RhB-µPLs appeared as square blocks in both cases, but starting from day 3 in acidic 
conditions, µPL merges appear less straight and, at day 10, µPLs structure appeared roundish and 
surrounded by spherical microparticles, possibly deriving from the self-assembly process of the 
eroded polymeric mass. All together these data prove that the degradation process of the particles 
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became a relevant phenomenon only at longer time point, when a significant portion of the drug 
has been already released. 
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Figure.3. µPL loading, release and biodegradation. A. Number of particles yielded from one 
sacrificial PVA template; B. Dexamethasone (DEX) loading into µPLs, using different PLGA 
amounts; C. Release profiles of DEX from PLs, realized with different PLGA amounts: 1 mg 
(grey), 5 mg (orange) and 7.5 mg (blue), in PBS buffer at pH 7.4; D. Release profiles of DEX from 
PLs, realized with different PLGA amount, 1 mg (grey), 5 mg (orange) and 7.5 mg (blue), in PBS 
buffer at pH 5.5; E. degradation of PLs under pathological (first 3 columns) and physiological 
(last column) conditions, monitored over time (1, 3, 6, and 10 days) via bright field, fluorescent 
and scanning electron microscopy. Results are expressed as average ± SD (n = 5). ANOVA 
analysis: *p ≤ 0.05. 
 
Therapeutic efficacy of Dexamethasone-loaded MicroPlates. µPLs made out of 5 mg of PLGA 
were selected for all in vitro studies, for they have better encapsulation efficiency and higher DEX 
amount per µPL as compared to the other two configurations. Before studying the interaction of 
µPLs with inflamed macrophages, the potential toxicity of empty µPLs (Figure.4A), free DEX 
(Figure.4B) and DEX-µPLs (Figure.4C) was assessed on phagocytic cell lines, such as RAW 
264.7 macrophages. Empty particles were tested at a cell to µPL ratios of 1:0.01, 1:0.05, 1:0.1, 1:1 
and 1:4. Cell viability was not significantly affected at any of the considered concentrations. 
Similarly, RAW 264.7 viability was not altered upon 24h incubation with free DEX or DEX-μPLs, 
even at the greatest tested concentration (30 μM). Note that 30 μM DEX is a concentration 3 times 
greater than the greatest concentration of DEX used for anti-inflammatory experiments. Also, the 
incubation time (24 h) was almost 3 times longer than the efficacy experiments, confirming that 
the DEX-μPLs can be efficiently used as a local drug delivery system. Based on these preliminary 
considerations, RAW 264.7 and primary bone marrow-derived macrophages (BMDMs) were 
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incubated with DEX-µPL, at 1 µM and 10 µM DEX concentrations, and then stimulated with LPS 
to induce the secretion of TNF-α, IL-1β and IL-6. Data are presented in Figure.4D for RAW 264.7 
cells and Figure.4E for BMDMs. Data clearly show that DEX-µPLs drastically reduce the 
secretion of all three considered inflammatory cytokines, in a concentration dependent manner. 
However, 1 µM of DEX-µPLs is already sufficient to decrease the expression of IL-1 and IL-6 
by two and three orders of magnitude, respectively, in the case of BMDMs. Interestingly, the 
strongest inhibitory effect was registered for the primary macrophages (BMDMs) that appear also 
to be more extensively stimulated by LPS as compared to RAW 264.7 cells.  
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Figure.4. Anti-inflammatory efficacy of DEX-µPLs. A-C. Viability of RAW 267.4 cells 
incubated with empty µPLs, free DEX and DEX-µPLs, respectively. D. and E. Pro-inflammatory 
cytokines expression levels for LPS stimulated RAW 267.4 and BMDM cells, respectively. (CTR: 
no LPS and no µPLs). Results are expressed as average ± SD (n = 3). 
 
Mechanical characterization of MicroPlates. μPLs are large, micron-sized particles that cannot 
be administered systemically but would rather function as local depots for the continuous and 
controlled release of therapeutic molecules and possibly nanoparticles. As such, the ability to 
modulate μPLs stiffness is a relevant factor in that it would facilitate their integration with the 
surrounding environment. Following this notion, the PLGA amount in the polymeric mixture for 
the µPLs preparation was changed, returning particles with different mechanical properties 
(Figure.5). First, atomic force microscopy (AFM) was used to assess μPLs morphology 
(Figure.5D), confirming overall the geometrical features already observed via scanning electron 
and fluorescent microscopies. Then, via AFM quantitative imaging mode, multiple force-
displacement curves were generated by indenting the PLs at different spots. Figure.5E shows a 
representative force-displacement curve. As reported in Figure.5F, PL stiffness increased with 
an increasing amount of PLGA, namely from 0.8 MPa for 1 mg of PLGA to 5.7 MPa for mg 
of PLGA. These values fall well within the Young’s modulus of native tissues.36 For instance, the 
stiffness value for 5 mg PLGA µPLs, which is of about 2.08 ± 0.5 MPa, is similar to the one of 
cartilage tissues.37 Nevertheless, this modulation in mechanical properties, by changing PLGA 
amount, do not affect µPLs size and shape. As from SEM images, besides a very moderate increase 
in central concavity, there is no morphological difference among µPLs realized with 1, 5 and 7.5 
mg of PLGA (Figure.5A-C, respectively).  
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The observed trend for the stiffness-PLGA amount relationship is in agreement with the well 
accepted notion that hydrogel stiffness can be modulated by changing polymer concentration.38 
Noteworthy, for polymeric nanoparticles obtained via a conventional bottom-up approach, an 
increase in polymer mass is generally associated with an increase in hydrodynamic diameter.39 In 
other words, the proposed top-down approach allows us to control the geometry and the 
mechanical properties of the particles simultaneously and independently.  
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Figure.5 Mechanical characterization of µPLs. A-C. SEM images of µPLs made out of 1.0, 5.0 
and 7.5 mg of PLGA, respectively D. Morphology of a µPL obtained via atomic force microscopy 
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(AFM) analysis. E. Representative force–displacement curve. Red curve represents the extension, 
while the blue one the retraction of AFM cantilever. F. Young’s modulus of µPLs realized with 
different amount of PLGA, namely 1.0, 5.0 and 7.5 mg. 
Preparation and characterization of DEX-SPNs-μPLs. Being conceived as a local drug delivery 
system, the size of µPLs is not appropriate for parenteral administration. However, multiple and 
different nanoparticles can be distributed, together with free drug molecules, within the µPL 
matrix, giving rise to a hierarchical multiscale system. As an example, drug-loaded spherical 
polymeric nanoconstructs (SPNs) were distributed within µPLs, thus realizing a hierarchical 
nanoconstruct spanning from the molecular size of the therapeutic payload to the nano-sized SPNs 
and micron-sized µPLs (Figure.6A). DEX-SPNs present an average size of 199.98 ± 25.87, a PDI 
value of 0.080 ± 0.010, and a -potential of – 40.50 ± 5.50 mV. DEX-SPNs were also characterized 
in terms of loading, returning a LE = 3.47 ± 1.22% and EE = 5.42 ± 0.74%. 
DEX-SPNs were dispersed within the polymeric paste used for assembling the µPLs and deposited 
over the template following the same approach used for DEX-µPLs. However, prior to their 
dispersion in the paste, DEX-SPNs were protected by a thin PVA coating which did not alter their 
physicochemical properties (see Figure.S3). At this point, the release of dexamethasone acetate 
from DEX-SPNs, DEX-μPLs, and DEX-SPNs-μPLs was studied. A direct comparison is shown 
in Figure.6B. For DEX-SPNs, about 90% of DEX was released within the first 8 h, whereas the 
remaining 10% was released within the following 48h. In the case of DEX-µPLs, only 60% of 
DEX was released during the first 8h, followed by a slow release until 10 days. Finally, the release 
from DEX-SPNs-μPLs was much slower: at 8h, only around 35% of DEX was released. This 
represents about 0.5 and 0.25 times the drug amounts released from DEX-SPNs and DEX-µPLs, 
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respectively. This trend slower release is observed throughout the whole experiment (240 h). Based 
on fitting considerations, the three release data are statistically different (p value < 0.0001). The 
entrapment efficiency of DEX-SPNs inside µPLs slows down DEX release, probably for the 
presence of the polymer matrix surrounding DEX-SPNs. In this case, water has to first penetrate 
and hydrate the µPLs matrix, and, after that, reach and hydrate the SPNs, as to free the drug 
molecules and starts their diffusion within the two polymeric matrices. Furthermore, the presence 
of the PVA surfactant on SPNs could contribute to this effect. The use of SPNs as drug carriers 
and loading them inside the PLs represents a strategy for modulating the release, especially within 
the first h, and for realizing truly multifunctional systems. 
To document the encapsulation and stability of SPNs within the µPL matrix, confocal fluorescent 
microscopy and transmission electron images were generated for SPNs loaded with gold 
nanoparticles and labeled with RhB (Figure.6C and D, and Figure.S4). The 20 nm spherical gold 
nanoparticles are clearly visible within the µPL matrix, whose particular structure can be 
appreciated in the TEM image of Figure.6C. The confocal image shows distinct red spots, rather 
than a diffuse fluorescence, confirming the intact structure and homogeneous distribution of SPNs 
after loading in the µPLs (Figure.6 D and Figure.S4). 
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Figure.6. Hierarchical, multifunctional µPLs. A. Schematic representation of µPL, DEX-SPN 
and DEX- SPNs-µPL. B. Release profile of DEX from DEX-SPNs (grey), DEX-PLs (orange) 
and DEX-SPNs-PLs (blue). Results are expressed as average ± SD (n = 3). C. TEM analysis of 
Au-Cy5-SPNs µPLs (scale bar 2µm). In the inset black spheres represent Au nanoparticles (200 
nm). D. Representative confocal tridimensional reconstruction of Au-Cy5-SPNs loaded inside one 
µPLs, showing their homogeneous distribution. 
 
CONCLUSION 
Micron-sized polymeric particles – the PLs – were realized using a top-down fabrication 
approach that allows us to control precisely and independently their geometrical, mechanical and 
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pharmacological properties. PLs have a square base with an edge length of 20 m and a height 
of 5 m. In previous works, using the same fabrication strategy, the authors have shown that 
particle geometry can be readily tailored.26-27 Furthermore, controlling the amount of PLGA allow 
us to realize PLs with different mechanical stiffness, without affecting the actual particle 
geometry. With a PLGA amount ranging from 1 to 7.5 mg, the PL Young’s modulus changed by 
one order of magnitude, namely from 0.6 MPa up to 5 MPa. The particle deformability is crucial 
in facilitating their deposition and integration with the surrounding tissues.  
In terms of pharmacological properties, the anti-inflammatory molecule Dexamethasone was 
dispersed within the PL matrix, and sustained release over a period of 10 days was demonstrated, 
with a significant burst within the first few h followed by a steady, continuous release. It was also 
shown that PL could be loaded with nanoparticles whereby such a hierarchical system can be 
used for building, in a modular way, multiple functionalities in the PLs. Specifically, it was 
demonstrated that the release profile of DEX could be modulated by dispersing within the PL 
matrix spherical polymeric nanoconstructs, loaded themselves with DEX, thus diminishing the 
initial burst release and modulating release throughout the whole process. 
Our findings evidence that µPLs can be used as a drug depot, combining sustained release profile, 
needed for all local drug delivery systems, with a precise control in geometrical and mechanical 
properties, fostering optimal tissue implantation. 
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Figure.S1. µPLs interaction with human fibroblasts monolayer. A. 3D confocal microscopy 
analysis of human fibroblasts cell after incubation with CURC-µPLs; B. representative Z-stack 
analysis demonstrating that CURC-µPLs are not internalized by human fibroblast but rather lodge 
on the cell membrane. 
  
41 
 
 
 
Figure.S2. Effect of PLGA amounts on µPLs loading. A. Mass of DEX loaded per µPL; B. 
Entrapment efficiency of DEX into µPLs. Results are expressed as average ± SD (n = 5). ANOVA 
analysis: *p ≤0.05, ***p ≤0.001 
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Figure.S3. Effect of PVA coating on DEX-SPN physicochemical properties. DLS size 
distribution of DEX-SPNs (blue line) and PVA-coated DEX-SPNs (red line), showing a very 
modest increase in size, due to the surface PVA coating. This is also confirmed by the slight 
increase in ζ-potential. 
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Figure.S4. Distribution of SPNs within the PL matrix. Representative confocal Z-stack image 
of a PL loaded with molecular curcumin (diffuse green color) and RhB-labeled SPNs (red spots). 
The latter are uniformly distributed within the green matrix of PLs  
